Floatz logo

Gefetinib

Metastatic Parathyroid Cancer

National Cancer Institute (NCI)N/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Metastatic Parathyroid Cancer cohort.

Asset / SponsorPhaseRating
Oxodotreotide
M.D. Anderson Cancer Center
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Bortezomib
Virginia Commonwealth University
Phase 1CC
Carboplatin
National Cancer Institute (NCI)
Phase 1CC

View all 9 →

Same molecule, other indications

Gefetinib is also rated in:

central nervous system neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
gliosarcomaDormant
BB
Indicative ·
71 / 100
View asset →
lung adenocarcinoma in situDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →